CT7439

CT7439 is a first-in-class, orally bioavailable small molecule inhibitor of cyclin-dependent kinases 12 and 13 (CDK12/13), developed by Carrick Therapeutics. In addition to its kinase inhibition, it acts as a "glue degrader" of Cyclin-K, the obligate co-factor for CDK12/13. This dual mechanism leads to potent inhibition of transcriptional-level DNA repair and gene transcription regulation via RNA Polymerase II initiation. The drug is being investigated primarily for advanced solid tumors—including breast cancer, ovarian cancer, and Ewing sarcoma—where it may also synergize with agents targeting DNA damage response such as PARP inhibitors. As of mid-2025, CT7439 is in Phase 1/2 clinical trials evaluating its safety and efficacy both as monotherapy and in combination with other anticancer treatments[1][2][3][4][5][6][7].